Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1. Pediatric subjects 0-12-months old.~   a. Including subjects born at ≥28 weeks of gestation.~2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24 hours and more.~3. Clinical score of between 7 to 10 at Screening (without oxygen supplementation).~4. Parent/guardian who is willing and able to sign, an informed consent on behalf of the subject.~Exclusion Criteria:~1. 1. Subjects diagnosed with alveolar pneumonia on Chest X-ray (including WBC≥ 15,000/ul, and Temp \>39°C).~2. Previous diagnosis of asthma or requirement for asthma medications.~3. Subjects with \>2 previous wheezing episodes.~4. History of life-threatening respiratory distress that requires admission to an intensive care unit for treatment.~5. Subjects with history of methemoglobinemia and/or methemoglobin \>5% for any cause.~6. Use of an investigational drug within 30 days before enrolment and/or expected to participate in a new study within 90 days.~7. History of frequent epistaxis (\>1 episode/month) or significant hemoptysis within 30 days prior to enrolment (≥5 mL of blood in one coughing episode or \>30 mL of blood in a 24-hour period.~8. Taken medications such as chronic systemic corticosteroids, CNS stimulants, theophylline or aminophylline, anti-arrhythmic within a certain time period prior to the study.~9. Unable to comply with the study procedures.~10. Underlying genetic disorders (including Cystic fibrosis) or hypotonia.~11. Having the following signs or symptoms: 1) known pulmonary (lung) and/or cardiac (heart) congenital malformations 2) an underlying renal, or liver insufficiency, immunodeficiency, encephalopathy; 3) known or suspected foreign body aspiration.~12. Any reason that, in the opinion of the investigator, may make the subject unfit for this clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Group 1 - Nitric Oxide treatment (Type: EXPERIMENTAL): • Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
- Group 2 - Control treatment (Type: ACTIVE_COMPARATOR): • Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).